Navigation Links
Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
Date:8/8/2011

ebsite (www.sec.gov) and on our website (www.orexigen.com) under the heading "Investor Relations." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Orexigen Therapeutics, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Six Months Ended June 30, June 30, 2011201020112010Revenues:Collaborative agreement $

857$

-$

1,714$

-License revenue 02297144Total revenues 857222,68544Operating expenses:Research and development 3,1315,5869,69813,567General and administrative 5,2046,18211,96312,203Total operating expenses 8,33511,76821,66125,770Loss from operations (7,478)(11,746)(18,976)(25,726)Other income (expense):Interest income 11342680Interest expense (101)(191)(221)(336)Total other income (expense) (90)(157)(195)(256)Net loss $

(7,568)$

(11,903)$

(19,171)$

(25,982)Net loss per share - basic and diluted $

(0.16)$

(0.25)$

(0.40)$

(0.55)Shares used in computing net loss per share – basic and diluted 48,08247,22547,97547,220Orexigen Therapeutics, Inc.Balance Sheets(In thousands, except share and par value amounts)June 30,December 31,20112010(Unaudited)AssetsCurrent assets:Cash and cash equivalents

$
36,400$
24,926Investment securities, available-for-sale

33,29867,440Prepaid expenses and other current assets

1,3092,502Total current assets

71,00794,868Property and equipment, net

654894Restricted cash

612881Other assets

11203Total assets

$
72,284$
96,846Liabilities and stockholders' equity Current liabilities:Accounts payable and accrued expenses

$
5,600$
,355Deferred revenue, current portion

3,4293,517Long-te
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 RnRMarketResearch.com adds Corneal ... report to its store. This report p provides ... The report "Corneal Ulcers - Pipeline Review, H2 ... for Corneal Ulcers. Corneal Ulcers are primarily result ... viral infections & fungal infections. The symptoms of ...
(Date:2/26/2015)... , Feb. 26, 2015  Today the ... The psychological and physical side effects of pain ... opioid painkillers, such as Vicodin and Oxycontin, are safer ... Americans overdose on prescription painkillers than on heroin and ... and CEO of NSC. "Yet, these medications are marketed ...
(Date:2/26/2015)... WASHINGTON , Feb. 26, 2015  Mail-service ... consumers, employers and government health plans ... research released by the Pharmaceutical Care Management Association ... specialty drugs offers one of the easiest ways ... CEO Mark Merritt . "Policymakers should resist ...
Breaking Medicine Technology:Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5National Safety Council: Opioid prescription painkillers have hidden, deadly side effects 2PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2
... Cumberland Pharmaceuticals Inc.(Nasdaq: CPIX ) today announced the ... of the supplemental new drug application (sNDA) for the use ... acute liver failure. The review has been extended by three ... (PDUFA) goal date in December 2010. "We ...
... 20 The European Patent Office ("EPO") Board ... to uphold European Patent No. EP 1307131 for ... http://photos.prnewswire.com/prnh/20061011/SFW044LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20061011/SFW044LOGO ... 26th, keeps the GlideScope patent in force in ...
Cached Medicine Technology:Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application 2Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application 3European Patent Office Upholds GlideScope® Video Laryngoscope Patent 2
(Date:3/1/2015)... Barrel Mill ” was featured on NewsWatch as part of ... latest and coolest technology products and services available to consumers. ... conducted the review and shared with viewers how this oak ... Distillation of Alcohol, it's understood that oak is essential for ... that’ll help anyone achieve a barrel aged alcohol without having ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 In recent years ... number of practicing physicians as a way for them to ... education regarding Cannabis as medicine. Since the FDA still lists ... few resources available to licensed physicians that can help ... patient. Dr. Deborah Malka in Santa Cruz, CA is ...
(Date:2/28/2015)... With their commitment to achieving physical results ... exercise to their already robust library of oblique exercises. ... known as, is often performed on a stationary piece ... a relatively safe manner and can be performed by ... description of “Rope Pulls” is located in the oblique ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate ... provide business consulting services in addition to a variety ... and succession planning. Company finances are a complicated matter ... top of this, complex Canadian tax laws can make ... a result, Mew and Company works to advise their ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 For those ... in person, the Mesothelioma Applied Research Foundation ... on Tuesday, March 3, starting at 9:30 AM. , ... no registration. The broadcast can be accessed through any ... http://www.curemeso.org/symposium . , The Symposium is a unique event ...
Breaking Medicine News(10 mins):Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2
... VPHM ) today announced that the Committee ... Agency (EMEA) has granted orphan,drug designation for CAMVIA ... with impaired cell-mediated immunity. The EMEA,s,"Orphan Medicinal Product ... which may provide significant benefit to patients,suffering from ...
... American Cancer Society,is looking for individuals with or without ... the battle against cancer to serve on peer,review committees ... the,organization,s research and training grants. These "stakeholders" have,often had ... had a,family member with cancer, having been a cancer ...
... spirometry to clinical exams benefits those with symptoms , MONDAY, ... diagnosing and treating the lung illness known as stable ... American College of Physicians (ACP). , COPD, typically caused ... affects more than 5 percent of American adults and is ...
... Stock Exchange Symbol: AKL, MONTREAL, Nov. 12 ... development company focused on developing therapies for the,inhalation ... from,its pilot GHRH Phase II study. Within only ... significant stimulation of endogenous growth hormone (GH),secretion and ...
... Now has,selected its $7,500 Grand Prize winner in its ... walks away with the big prize,after a 3-month competition ... will receive $250 in the contest. The winning video ... "Brendan Hayward captured, in just 30 seconds, what ...
... Inc. (OTC Bulletin Board: INIS) announces financial results ... 30, 2007. REVENUE: Revenue for the three ... and $3,592,049 respectively, as compared to,$1,458,260 and $3,641,098 ... an increase of 2% for the three-month period ...
Cached Medicine News:Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 2Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 3Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 4Health News:American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 2Health News:New Guideline Targets Treatment of Stable COPD 2Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 2Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 3Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 4Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 5Health News:Psoriasis Cure Now Video Contest $7,500 Grand Prize Winner Announced 2Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 2Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 3Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 4
... The Finnpipette Digital offers improved ... The rounded handle, modified grippy finger ... enhance operator comfort and efficiency. Finnpipette ... with power-boosted gearing mechanism (pat. pend.) ...
... The AlphaPette Pipettor is the ... beyond. Offers accuracy, comfort, and reliability. ... digital volume readout sub-micrometer. Easy interchangeable ... or tiny hands. Adjustable rapid pipet ...
... for aqueous samples of moderate viscosity and density. Proven ergonomic design reduces ... Volume Range(ul) ... 0.8~1.5 Imprecision(%) ... 10 ...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Medicine Products: